



Denis COMET

Denis Comet (1960), Médecin, diplôme universitaire en méthodologie appliquée à la recherche clinique, diplôme universitaire en évaluation de la santé, formation au management (HEC), membre de l'association des épidémiologistes de langue française (ADELF).

Cofondateur en 1989 avec d'autres médecins et président de la société Axonal-Biostatem, société de services CRO (Clinical Research Organization) dans le top 3 des CRO françaises en recherche clinique, leader dans les études post enregistrement (post-AMM). Notre activité est principalement (70 %) sur ces études post-AMM, registres, observatoires, études dites dans la "vraie vie", dans le domaine du médicament, du dispositif médical (20% du chiffre d'affaires) et de la nutrition, et pour 30% sur les essais cliniques de phase II et III, essentiellement en oncologie. Au cours des 6 dernières années, Axonal-Biostatem a créé des partenariats privilégiés avec des CRO locales dans d'autres pays et est devenue une société européenne.

Activités associatives professionnelles : président de AFCROs (Association Française des CRO), membre et ancien coordonnateur du groupe de travail en pharmaco-épidémiologie de AFCROs.

Co-animateur du Groupe de travail sur les études post enregistrement de l'EUCROF (Fédération européenne des CRO) et représentant français au sein de l'EUCROF.

--

Denis COMET

Denis Comet (1960, MD), university degree in methodology applied to clinical research, university degree in health evaluation, management course in HEC school, member of the French epidemiologists association (ADELF).

After several years of freelance work in medical writing for the pharmaceutical industry and medical press, I founded the company Axonal-Biostatem in 1989 with other physicians, a French full services CRO (Clinical Research Organization) in the top 3 of French independent CRO and leader in observational research, where I hold the position of CEO. Our business is mainly (70%) on Real World Studies (post-approval studies) in the field of drug, medical device (20% of our revenues) and nutrition; 30% in Phase II and III CT, essentially in oncology. In the last 6 years, we worked with other local CROs, and Axonal-Biostatem become an European company thru those partnerships.

Professional and associative memberships: President of AFCROs (Association Française des CROs, CROs french association), member and former coordinator of pharmacoepidemiology working group of AFCROs.

Actual co-chair of Late Phase Working Group of EUCROF (EU CRO Federation) and former French representative at the board of EUCROF.

On the associative side, I have participated in the creation of the French association (AFCROs) 12 years ago now, and I am the actual President of the association. I founded and coordinate a working group (WG) on pharmacoepidemiology (this WG co-organize a scientific symposium on that topic with ADELFF every 2 years, 200-250 attendees, 70 oral presentations and posters, published abstracts ), I also participate to our Training WG (GCP, Data Privacy, etc. ...) with 8-12 annual meetings for our members, and was former representative person of France at EUCROF (European CRO Federation).